The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Kumar Ravindra since 2014.
The trader's CIK number is 1586835.
At the time of the last reporting, Kumar Ravindra was the VP & Chief Scientific Officer of Acceleron Pharma Inc. (stock ticker symbol XLRN).
Also see all insider trading activities at Acceleron Pharma Inc.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2019 | XLRN | 0 | $0 | 12,799 | $565,509 | 0 | $0 |
| 2018 | XLRN | 0 | $0 | 5,503 | $228,978 | 0 | $0 |
| 2017 | XLRN | 0 | $0 | 21,115 | $745,658 | 20,763 | $357,366 |
| 2016 | XLRN | 0 | $0 | 52,486 | $1,791,017 | 58,162 | $615,896 |
| 2015 | XLRN | 0 | $0 | 49,500 | $1,812,146 | 37,551 | $172,130 |
| 2014 | XLRN | 0 | $0 | 64,000 | $2,078,998 | 53,810 | $267,561 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2019-09-10 | XLRN | Sale | 3,389 | 45.24 | 153,318 |
| 2019-04-09 | XLRN | Sale | 3,622 | 44.77 | 162,167 |
| 2019-01-02 | XLRN | Sale | 5,788 | 43.20 | 250,024 |
| 2018-04-03 | XLRN | Sale | 1,203 | 38.75 | 46,616 |
| 2018-01-02 | XLRN | Sale | 4,300 | 42.41 | 182,362 |
| 2017-09-28 | XLRN | Option Ex | 6,761 | 5.28 | 35,698 |
| 2017-09-13 | XLRN | Sale | 8 | 38.12 | 304 |
| 2017-09-12 | XLRN | Sale | 5,105 | 38.85 | 198,329 |
| 2017-08-08 | XLRN | Option Ex | 13,065 | 24.11 | 314,997 |
| 2017-08-08 | XLRN | Sale | 13,065 | 35.41 | 462,631 |
| 2017-07-05 | XLRN | Sale | 937 | 32.00 | 29,984 |
| 2017-07-05 | XLRN | Option Ex | 937 | 7.12 | 6,671 |
| 2017-01-04 | XLRN | Sale | 2,000 | 27.20 | 54,410 |
| 2016-12-22 | XLRN | Option Ex | 14,561 | 4.58 | 66,689 |
| 2016-10-07 | XLRN | Sale | 19,644 | 33.69 | 661,708 |
| 2016-10-06 | XLRN | Sale | 16,009 | 34.65 | 554,631 |
| 2016-10-07 | XLRN | Option Ex | 19,644 | 9.13 | 179,428 |
| 2016-10-06 | XLRN | Option Ex | 7,124 | 5.28 | 37,614 |
| 2016-10-10 | XLRN | Sale | 16,833 | 34.14 | 574,678 |
| 2016-10-10 | XLRN | Option Ex | 16,833 | 19.73 | 332,165 |
| 2015-10-19 | XLRN | Option Ex | 14,066 | 4.05 | 57,009 |
| 2015-09-15 | XLRN | Sale | 33,000 | 35.00 | 1,155,000 |
| 2015-09-15 | XLRN | Option Ex | 11,485 | 3.88 | 44,561 |
| 2015-03-04 | XLRN | Option Ex | 4,000 | 5.88 | 23,520 |
| 2015-03-04 | XLRN | Sale | 5,500 | 41.27 | 226,957 |
| 2015-02-02 | XLRN | Sale | 5,500 | 38.88 | 213,867 |
| 2015-02-02 | XLRN | Option Ex | 4,000 | 5.88 | 23,520 |
| 2015-01-12 | XLRN | Sale | 1,500 | 40.58 | 60,862 |
| 2015-01-02 | XLRN | Option Ex | 4,000 | 5.88 | 23,520 |
| 2015-01-02 | XLRN | Sale | 4,000 | 38.87 | 155,460 |
| 2014-12-19 | XLRN | Option Ex | 9,810 | 1.36 | 13,341 |
| 2014-12-01 | XLRN | Option Ex | 4,000 | 5.88 | 23,520 |
| 2014-12-01 | XLRN | Sale | 4,000 | 36.14 | 144,548 |
| 2014-11-12 | XLRN | Option Ex | 4,000 | 5.88 | 23,520 |
| 2014-11-13 | XLRN | Option Ex | 10,000 | 5.58 | 55,800 |
| 2014-11-12 | XLRN | Sale | 4,000 | 33.01 | 132,040 |
| 2014-11-13 | XLRN | Sale | 12,000 | 35.00 | 420,000 |
| 2014-10-01 | XLRN | Option Ex | 4,000 | 5.88 | 23,520 |
| 2014-09-30 | XLRN | Sale | 7,000 | 30.00 | 210,000 |
| 2014-09-30 | XLRN | Option Ex | 5,000 | 5.58 | 27,900 |
| 2014-10-01 | XLRN | Sale | 4,000 | 29.96 | 119,860 |
| 2014-09-02 | XLRN | Sale | 2,000 | 26.40 | 52,800 |
| 2014-09-02 | XLRN | Option Ex | 2,000 | 5.88 | 11,760 |
| 2014-08-14 | XLRN | Option Ex | 5,000 | 5.88 | 29,400 |
| 2014-08-14 | XLRN | Sale | 9,000 | 29.93 | 269,325 |
| 2014-07-01 | XLRN | Sale | 2,000 | 34.10 | 68,200 |
| 2014-06-20 | XLRN | Option Ex | 5,000 | 5.88 | 29,400 |
| 2014-06-20 | XLRN | Sale | 7,000 | 35.00 | 245,000 |
| 2014-06-02 | XLRN | Sale | 2,000 | 29.72 | 59,440 |
| 2014-05-19 | XLRN | Option Ex | 5,000 | 5.88 | 29,400 |
| 2014-05-19 | XLRN | Sale | 9,000 | 31.79 | 286,065 |
| 2014-04-22 | XLRN | Sale | 2,000 | 35.86 | 71,720 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kumar Ravindra (VP & Chief Scientific Officer of Acceleron Pharma Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.